More than 1 million men in the United States have transrectal ultrasound (TRUS) guided prostate biopsies each year due to a combination of risk factors such as elevated PSA levels, physical exam abnormalities and family history. Less than 10% of the 12 million biopsy core samples that are taken and analyzed come back positive for cancer (at a cost of nearly $1 billion dollars).

Additionally, these TRUS guided prostate biopsies miss about 20% to 30% of cancers that require therapy. This is unfortunate because some prostate cancers are aggressive, killing some 28,000 men on average in the U.S. each year, according to the American Cancer Society. In fact, prostate cancer is the second most deadly cancer in men, after lung cancer.

It’s clear today’s standard prostate biopsies leave a lot to be desired for doctors, patients, and the healthcare system.

Doctors need a way to classify prostate tissue during the actual biopsy procedure so they can make better patient management decisions. Patients deserve better real-time information and detection. And the healthcare system shouldn’t have to absorb such inefficiencies.